Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Viridian Therapeutics ( (VRDN) ) has shared an announcement.
On May 11, 2026, Viridian Therapeutics completed a $250 million public offering of 1.75% Convertible Senior Notes due 2032, following a May 6 underwriting agreement that included a $25 million over‑allotment exercised in full. The notes, which are senior unsecured obligations with detailed conversion, redemption and default provisions, may be settled in cash, stock or a combination, and could result in the issuance of up to about 14.7 million shares depending on conversion adjustments.
In a parallel capital raise, Viridian closed an equity offering on May 11, 2026 of 7,352,942 common shares at $17.00 per share, generating approximately $117 million in net proceeds, and brought total net proceeds from both the equity and convertible offerings to roughly $359 million. The company plans to use this expanded financing capacity to repay its Hercules Capital loan, fund market expansion studies for its thyroid eye disease franchise, and advance earlier‑stage R&D, steps that are expected to strengthen its balance sheet and support long‑term growth initiatives.
The most recent analyst rating on (VRDN) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.
Spark’s Take on VRDN Stock
According to Spark, TipRanks’ AI Analyst, VRDN is a Neutral.
The score is held down primarily by very large ongoing losses and heavy free-cash-flow burn despite only modest revenue, while technicals also show a weak longer-term trend (below key moving averages, negative MACD). Offsetting these negatives, the balance sheet leverage is low and recent Phase 3 successes meaningfully improve the clinical/regulatory outlook, lifting the overall assessment into the low-50s.
To see Spark’s full report on VRDN stock, click here.
More about Viridian Therapeutics
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for thyroid eye disease and earlier‑stage pipeline programs. The company operates in the U.S. healthcare sector and is positioning its thyroid eye disease franchise for market expansion while continuing to invest in research and development.
Average Trading Volume: 2,698,035
Technical Sentiment Signal: Sell
Current Market Cap: $1.71B
Find detailed analytics on VRDN stock on TipRanks’ Stock Analysis page.